

San Antonio Breast Cancer Symposium

Henry B. Gonzalez Convention Centre

December 10-13, 2024

Abstracts

CCTG MA.27 – A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer

Type: Poster

Session: Poster Session 1

Abstract: **Adjunctive statistical standardization of quantitated adjuvant HER2 and very low statistically standardized HER2 in CCTG MA.27**

Abstract #: P1-07-06

Authors: Chapman JA, Bayani J, SenGupta S, Bartlett JMS, Piper T, Quintayo MA, Virk S, Goss PE, Ingle JN, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Gelmon KA, Whelan TJ, Elliott E, Shepherd LE, Chen BE, Taylor KJ

Page #: 241 of the Abstracts program

ECOG PACCT-1/CCTG MAC.12 - Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial

Type: Poster

Session: Poster Session 4

Abstract: **Development of ASSESS, a breast cancer decision support tool using SEER data and treatment benefit estimates from randomized adjuvant therapy trials.**

Abstract #: P4-04-04

Authors: Michal Marczyk, Joanna Tobiasz, Mariya Rozenblit, Robert J. Volk, Balázs Győrffy, Lajos Pusztai, Sharon H. Giordano

Page#: 1241 of the Abstracts program

Alliance A011202/CCTG MAC.19 - A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1 -3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Type: Oral
Session: Rapid Fire 2
Abstract: **Factors Influencing Additional Nodal Disease and Pathologic Nodal Upstaging with Axillary Dissection in Patients with Residual NodePositive Breast Cancer After Neoadjuvant Chemotherapy Enrolled on Alliance A011202 Clinical Trial**
Abstract #: RF2-01
Authors: Judy Boughey, Vera Suman, Kelly J. Hunt, Bruce G. Haffty, Thomas Buchholz, W. Fraser Symmans, Tracy L. Rieken, Travis J. Dockter, Jordan D. Campbell, Anna Weiss, Julie A. Bradley, Joshua M. V. Mammen, Ann H. Partridge, Lisa A. Carey
Page#: 2162 of the Abstracts program

ALLIANCE A011404/CCTG MAC.20 - Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Type: Oral
Session: Rapid Fire 1
Abstract: **Effect of a weight loss intervention (WLI) on metabolic and inflammatory biomarkers in women with obesity and breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial (Alliance)**
Abstract #: RF1-01
Authors: Jennifer Ligibel, Karla V. Ballman, Linda McCall, Lingeng Lu, Melinda Irwin, Pamela J. Goodwin, Catherine M. Alfano, Vanessa Bernstein, Tracy E. Crane, Linda M. Delahanty, Elizabeth Frank, Olwen Hahn, Dawn L. Hershman, Judith O. Hopkins, Erica L. Mayer, Lori Minasian, Linda Nebeling, Marian L. Neuhouser, Electra D. Paskett, Patricia A. Spears, Vered Stearns, Cynthia A. Thomson, Anna Weiss, Julia White, Thomas A. Wadden, Clifford Hudis, Eric P. Winer,, Lisa A. Carey, Ann H. Partridge
Page #: 2154 of the Abstracts program

ALLIANCE A011404/CCTG MAC.20 - Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Type: Poster
Session: Poster Session 3
Abstract: **Trajectories of Daily Step Counts in Breast Cancer Survivors in the Breast Cancer Weight Loss (BWEL) Trial**
Abstract #: P3-06-15
Authors: Chao Cao, Karla V. Ballman, Linda McCall, Thomas A. Wadden, Catherine M. Alfano, Xiaolan Feng, Linda M. Delahanty, Elizabeth Frank, Olwen Hahn, Dawn L. Hershman, Judith O. Hopkins, Melinda Irwin, Erica L. Mayer, Lori Minasian, Linda Nebeling, Marian L. Neuhouser, Electra D. Paskett, Patricia A. Spears, Vered Stearns, Cynthia A. Thomson, Anna Weiss, Julia White, Pamela J. Goodwin, Clifford Hudis, Eric P. Winer, Ann H. Partridge, Lisa A. Carey, Jennifer A. Ligibel
Page #: 988 of the Abstracts program

ALLIANCE A011502/CCTG MAC.21 - A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

Type: Poster
Session: Poster Session 5
Abstract: **Association of Baseline Global Inflammation Score with Clinical Outcomes: Secondary Analysis from Alliance A011502**
Abstract #: P5-08-12
Authors: Shipra Gandhi, Karla V. Ballman, Sarah K. Reed, Michelle D. Holmes, Kala Visvanathan, Banu Symington, Margaret Carvan, Carol Matyka, Anna Weiss, Eric P. Winer, Wajeeha Razaq, Paula R. Pohlmann, Lisa A. Carey, Ann H. Partridge, Wendy Y. Chen
Page #: 1810 of the Abstracts program

NRG BR004/CCTG MAC.25 – A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/ Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Type: Oral
Session: Rapid Fire 3
Abstract: **A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-positive Metastatic Breast Cancer**
Abstract #: RF3-04
Authors: Valero V, Tang B, Geyer Jr, CE, Rastogi P, Puhalla SL, Li J, Chia SKL, Cobain EF, Obeid E, Page DB, Poklepovic AS, Irvin Jr WJ, Brufsky AM
Page #: 2172 of the Abstracts program

NRG BR007/CCTG MAC.28 - A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer (DEBRA)

Type: Poster
Session: Poster Session 2
Abstract: **A phase III trial evaluating De-escalation of Breast Radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤ 18 breast cancer:**
Abstract #: P2-12-25
Authors: Julia R. White, Reena S. Cecchini, Eleanor E.R. Harris, Eleftherios P. Mamounas, Daniel G. Stover, Patricia A. Ganz, Reshma Jagsi, Stewart J. Anderson, Carmen Bergom, Valérie Théberge, Mahmoud El-Tamer, Richard C. Zellars, Dean A. Shumway, Guang-Pei Chen, Thomas B. Julian, Norman Wolmark
Page #: 804 of the Abstracts program

NRG BR009/CCTG MAC.30 - A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score \leq 25 (OFSET)

Type: Poster

Session: Poster Session 3

Abstract: **A phase III trial evaluating addition of adjuvant chemotherapy to Ovarian Function Suppression + Endocrine Therapy in premenopausal women with pN0-1, HR+/HER2-breast cancer (BC) and Oncotype Recurrence Score (RS) \leq 25 (OFSET)**

Abstract #: P3-12-20

Authors: Shannon L. Puhalla, Gong Tang, Sandra M. Swain, Patricia A. Ganz, N. Lynn Henry, Reena S. Cecchini, Sonya A. Reid, Priya Rastogi, Charles E. Geyer, Jr., Julia R. White, Amy S. Clark, Tufia C. Haddad, Gregory A. Vidal, Norman Wolmark, Eleftherios P. Mamounas

Page #: 1190 of the Abstracts program
